-
Mashup Score: 0Advances in the clinical management of uveal melanoma - Nature Reviews Clinical Oncology - 1 year(s) ago
Although almost all patients with uveal melanoma have localized disease at diagnosis, and despite effective treatment of the primary tumour, metastatic recurrence is common and holds a dismal prognosis. Unlike its cutaneous counterpart, therapeutic advances for uveal melanoma have not been forthcoming, although the recent approval of the first systemic therapy for this disease has ushered in a…
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC) [Sep 12, 2022] @mgfakih et al. #ESMO22 Abstract 320MO https://t.co/srGejEmuKe #NCT04362839 #crcsm #ImmunoOnc #camets https://t.co/w4jtkDqUQs
-
-
Mashup Score: 0
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC) [Sep 12, 2022] @mgfakih et al. #ESMO22 Abstract 320MO https://t.co/srGejEn2zM #NCT04362839 #crcsm #ImmunoOnc #camets
-
-
Mashup Score: 0Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @Tempus
-
-
Mashup Score: 0JNCCN 360 - Bladder - Upper Tract Urothelial Cancer: Prognostic Relevance of the Site of Metastases - 2 year(s) ago
By: Celeste L. Dixon Posted: Thursday, October 13, 2022 The location of metastases in patients with metastatic upper tract urothelial carcinoma appears to have prognostic significance, according to research based on Surveillance, Epidemiology, and End Results (SEER) data published in the Journal of Clinical Medicine by…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read About Upper Tract #UrothelialCancer: Prognostic Relevance of the Site of Metastases on #JNCCN360: https://t.co/jFJhy9uz93 #BLCSM #camets https://t.co/1ikgbv7oOb
-
-
Mashup Score: 0
Abstract. Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from academic and community cancer centers, but there is a lack of information on testing…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1YfsySU #PrecisionMedicine #crcsm #camets https://t.co/b7O5O74C3B
-
-
Mashup Score: 0Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6Yb3n #PrecisionMedicine #LiquidBiopsy #camets @Tempus
-
-
Mashup Score: 1Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6H81n #PrecisionMedicine #LiquidBiopsy #camets @Tempus
-
-
Mashup Score: 0Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6H81n #PrecisionMedicine #LiquidBiopsy #camets @TempusLabs https://t.co/9jhQ3ndTAp
-
-
Mashup Score: 0
Abstract. Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from academic and community cancer centers, but there is a lack of information on testing…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1YfsySU #PrecisionMedicine #crcsm #camets https://t.co/lgRAMiyLcR
-
In a new Review now live online, Richard Carvajal et al. discuss key advances in the clinical management of uveal melanoma: https://t.co/HxbrnrNngV @ColumbiaCancer #melsm #ImmunoOnc #medonc #camets #cagenome https://t.co/asJchnEMSF